Drugs That Distort Your FSH Test: A Complete Medication Guide

What FSH Measures and Why Drug Interference Matters

FSH is a glycoprotein hormone secreted by the anterior pituitary gland. It stimulates ovarian follicle development in women and spermatogenesis in men. Clinicians order FSH to evaluate infertility, confirm menopausal status, diagnose hypogonadism, and assess pituitary function. A single misleading value can reroute an entire treatment plan.

The hypothalamic-pituitary-gonadal (HPG) axis operates through negative feedback: when estradiol or testosterone levels are high, the pituitary reduces FSH output 1. Any drug that mimics, blocks, or alters sex steroid signaling will shift FSH. The Endocrine Society's 2019 clinical practice guideline on male hypogonadism specifically warns that "testosterone therapy suppresses gonadotropins and spermatogenesis" and that FSH should not be measured while a patient is on exogenous androgens 2. Beyond hormonal drugs, even over-the-counter supplements like biotin can corrupt the immunoassay itself, producing a number that has nothing to do with pituitary function.

The practical problem is straightforward. Patients rarely volunteer a full medication list before lab work, and ordering clinicians may not ask about supplements. A 2020 survey published in the Journal of the Endocrine Society found that 47% of patients taking biotin-containing supplements did not disclose them to their provider before hormone testing 3. The result is avoidable misdiagnosis.

Oral Contraceptives and Hormonal Contraception

Combined oral contraceptives (COCs) are the most common FSH suppressors. They work. COCs containing ethinyl estradiol plus a progestin (norethindrone, levonorgestrel, drospirenone) suppress pituitary gonadotropin release as their primary mechanism of action 4.

FSH levels on COCs typically fall below 2 mIU/mL, well under the follicular-phase reference range of 3.5 to 12.5 mIU/mL. This suppression persists with progestin-only methods as well, though to a lesser degree. Depot medroxyprogesterone acetate (Depo-Provera) suppresses FSH by approximately 15 to 20%, while the levonorgestrel IUD has minimal systemic effect on gonadotropins in most users 5.

The clinical trap: a woman on COCs who gets FSH drawn to evaluate fertility will show suppressed levels that mimic hypopituitarism. The Endocrine Society recommends discontinuing COCs for at least four to six weeks before measuring FSH for ovarian reserve assessment 1. Clinicians evaluating perimenopause should draw FSH on cycle days 2 to 5 of a natural (unmedicated) menstrual cycle for reliable results.

GnRH Agonists and Antagonists

Gonadotropin-releasing hormone (GnRH) drugs produce a biphasic FSH response that confuses interpretation if the timing is not understood.

GnRH agonists (leuprolide, goserelin, nafarelin, triptorelin) initially stimulate the pituitary, causing a "flare" of FSH and LH lasting 7 to 14 days. After this flare, receptor downregulation drives FSH to castrate levels, typically below 1 mIU/mL by week four 6. A study of 146 men receiving leuprolide for prostate cancer showed mean FSH levels of 1.2 mIU/mL at 12 weeks, compared to a pretreatment mean of 9.8 mIU/mL 6.

GnRH antagonists (degarelix, cetrorelix, ganirelix, elagolix) bypass the flare entirely. They competitively block the GnRH receptor and suppress FSH within 24 to 72 hours 7. Elagolix (Orilissa), prescribed for endometriosis pain, reduces FSH in a dose-dependent fashion: the 150 mg once-daily dose produces partial suppression, while 200 mg twice daily suppresses FSH nearly to postmenopausal levels in the opposite direction, creating a clinical paradox where a premenopausal woman on elagolix may show FSH values that suggest ovarian failure 7.

The American Society for Reproductive Medicine (ASRM) states that "FSH values obtained during GnRH agonist or antagonist therapy do not reflect ovarian reserve and should not be used for fertility counseling" 8.

Clomiphene, Letrozole, and Selective Estrogen Receptor Modulators

Drugs that block estrogen's negative feedback on the pituitary will raise FSH. This is the intended mechanism for ovulation induction, but it distorts FSH interpretation when the test is ordered for diagnostic (not treatment-monitoring) purposes.

Clomiphene citrate (Clomid) blocks estrogen receptors in the hypothalamus and pituitary. The pituitary "sees" low estrogen and increases FSH secretion. In the landmark study by Dickey et al., clomiphene 100 mg daily for five days raised mid-cycle FSH by 50 to 100% above baseline in anovulatory women 9. FSH remains elevated for 10 to 14 days after the last dose.

Letrozole (Femara) lowers estradiol by inhibiting aromatase, which indirectly raises FSH through reduced negative feedback. A randomized trial of 750 women (the AMIGOS trial, N=900 total across three arms) showed that letrozole 2.5 mg produced mean FSH levels 30% higher than natural-cycle FSH on stimulation day 3 10.

Tamoxifen and raloxifene have mixed agonist-antagonist effects depending on tissue. In premenopausal women, tamoxifen 20 mg daily raises FSH by approximately 30% through hypothalamic estrogen receptor blockade 11. In postmenopausal women, the effect is less pronounced because baseline estradiol is already low.

Testosterone, Anabolic Steroids, and Androgen Therapy

Exogenous testosterone is the most potent FSH suppressor that clinicians routinely overlook during lab interpretation. Men on testosterone replacement therapy (TRT) typically show FSH levels below 0.5 mIU/mL within 8 to 12 weeks of initiation.

The mechanism is direct. Exogenous testosterone and its aromatized metabolite estradiol both suppress pituitary gonadotropin secretion. The Testosterone Trials (TTrials, N=790) documented that men receiving testosterone gel 1% had mean FSH levels of 0.7 mIU/mL at 12 months versus 5.1 mIU/mL in the placebo group 12. This 86% suppression is clinically indistinguishable from pituitary failure on the lab report alone.

Anabolic steroids (nandrolone, oxandrolone, stanozolol) produce identical suppression. So does DHEA at high doses (above 50 mg daily), though the effect is milder. The 2018 Endocrine Society guideline on testosterone therapy warns: "Clinicians should not measure gonadotropins to diagnose or monitor hypogonadism in men receiving testosterone therapy, as these values will be suppressed and do not reflect underlying hypothalamic-pituitary function" 2.

Women receiving testosterone for hypoactive sexual desire disorder (HSDD) at physiologic doses (300 mcg/day transdermal) show modest FSH reductions of 10 to 15%, generally remaining within the reference range 13.

Glucocorticoids and Stress-Axis Medications

Chronic glucocorticoid use suppresses the entire hypothalamic-pituitary axis, including gonadotropin secretion. Prednisone at doses above 7.5 mg daily for more than three weeks reduces FSH by 15 to 30%, with the effect proportional to dose and duration 14.

The mechanism involves both direct pituitary suppression and indirect effects through cortisol-mediated inhibition of GnRH pulsatility. A prospective study of 84 patients with rheumatoid arthritis on prednisone 10 mg daily for six months showed mean FSH levels 22% lower than matched controls not on glucocorticoids 14.

Megestrol acetate (Megace), a progestational agent used as an appetite stimulant, suppresses FSH through progestational negative feedback. Ketoconazole at antifungal doses (200 to 400 mg daily) inhibits steroidogenesis, lowers testosterone and cortisol, and can paradoxically raise FSH in men through reduced androgen-mediated feedback 15.

Opioids deserve attention here. Chronic opioid use (morphine, oxycodone, methadone, buprenorphine) suppresses the HPG axis, producing opioid-induced hypogonadism in 21 to 86% of men on long-term therapy. FSH may fall to hypogonadal levels, mimicking pituitary disease 16.

Antiepileptic Drugs and Psychotropics

Several neuropsychiatric medications alter FSH through diverse mechanisms.

Valproate (Depakote) is associated with polycystic ovary syndrome (PCOS)-like changes in women, including altered FSH-to-LH ratios. A study of 60 women on valproate monotherapy found a mean FSH of 4.1 mIU/mL compared to 6.2 mIU/mL in controls (P<0.01), with a concurrent shift toward elevated LH 17.

Carbamazepine and phenytoin induce hepatic cytochrome P450 enzymes, increasing sex hormone-binding globulin (SHBG) and altering the free fraction of sex steroids. The net effect on FSH is variable but can produce modest elevations (10 to 20%) in men through reduced bioavailable testosterone 18.

Antipsychotics that raise prolactin (risperidone, haloperidol, paliperidone) can suppress FSH indirectly. Prolactin inhibits GnRH pulsatility, and hyperprolactinemia from antipsychotics produces functional hypogonadotropic hypogonadism with low FSH and LH. Risperidone elevates prolactin in up to 70% of patients, with corresponding gonadotropin suppression in a subset 19.

Biotin and Supplement-Based Assay Interference

Biotin (vitamin B7) does not change circulating FSH concentrations. It corrupts the laboratory assay itself. This distinction matters because the "false" result has nothing to do with your physiology.

Many modern immunoassays for FSH use a streptavidin-biotin capture system. When serum biotin levels exceed approximately 30 ng/mL (achievable with daily doses above 5 mg), excess biotin competes with the assay's biotinylated antibody, producing falsely low results in sandwich assays and falsely high results in competitive assays 20. Most FSH assays are sandwich format, meaning biotin interference drives the reported FSH value down.

The FDA issued a 2017 safety communication warning that "biotin can significantly interfere with certain lab tests and cause incorrect test results" after receiving adverse event reports including one death attributed to falsely low troponin results from biotin interference 20. The agency recommended discontinuing biotin at least 72 hours before blood work, though some experts suggest a longer washout of 7 days for megadose biotin (10 mg or above) used in hair-and-nail supplements 21.

Hair growth supplements frequently contain 2,500 to 10 to 000 mcg (2.5 to 10 mg) of biotin. Patients taking these products often do not consider them "medications" and fail to report them. The practical fix: ask every patient about supplements, specifically naming biotin, before ordering hormone panels.

How to Get an Accurate FSH Result

Timing the blood draw correctly is half the battle. The other half is medication management.

Pre-test medication review: Compile a full list of prescription drugs, over-the-counter medications, and supplements. Flag any agent from the categories above. Discuss with the ordering clinician whether a washout period is feasible and safe before the draw.

Washout timelines by drug class:

• Oral contraceptives: 4 to 6 weeks (two natural cycles)
• GnRH agonists: 8 to 12 weeks after last injection
• GnRH antagonists: 2 to 4 weeks after last dose
• Clomiphene or letrozole: 14 days after last dose
• Testosterone injections (cypionate/enanthate): 4 to 6 weeks after last injection
• Testosterone gel: 2 to 4 weeks after stopping
• Glucocorticoids (chronic): discuss taper with prescriber; do not stop abruptly
• Biotin: 72 hours minimum; 7 days for doses above 5 mg

Timing within the menstrual cycle: For ovarian reserve evaluation, draw FSH on cycle day 2, 3, or 4 of a natural menstrual cycle. The ASRM and the American College of Obstetricians and Gynecologists (ACOG) both specify early follicular-phase sampling as the standard 8.

Fasting: FSH does not require fasting, but if the sample is drawn alongside a metabolic panel, a morning fasted sample reduces variability.

Repeat testing: A single FSH value rarely dictates clinical decisions. The Endocrine Society recommends confirming abnormal FSH results with at least one repeat measurement, ideally drawn four weeks apart and under the same conditions 2.

Normal FSH Ranges and What Abnormal Values Mean

Reference ranges vary by laboratory, sex, age, and menstrual cycle phase. The values below reflect consensus ranges from major reference laboratories.

Women (premenopausal):

• Follicular phase: 3.5 to 12.5 mIU/mL
• Mid-cycle peak: 4.7 to 21.5 mIU/mL
• Luteal phase: 1.7 to 7.7 mIU/mL

Women (postmenopausal): 25.8 to 134.8 mIU/mL

Men: 1.5 to 12.4 mIU/mL

Children (prepubertal): 0.3 to 3.0 mIU/mL

High FSH (above the upper limit for age and sex) suggests diminished ovarian reserve or primary ovarian insufficiency in women, and primary testicular failure (Klinefelter syndrome, post-chemotherapy damage) in men. The pituitary is working harder because the gonads are not responding.

Low FSH (below the lower limit) points toward hypothalamic or pituitary dysfunction (secondary hypogonadism), or suppression by exogenous hormones, medications, or severe illness. A 2021 meta-analysis of 12 studies found that FSH below 1.0 mIU/mL in men had a positive predictive value of 89% for exogenous androgen use when other pituitary pathology was excluded 22.

The FSH-to-LH ratio also carries diagnostic weight. In PCOS, the ratio often inverts (LH exceeding FSH by 2:1 or more), though this finding is no longer required for diagnosis under the Rotterdam criteria 23.

When to Retest After Stopping a Medication

Recovery timelines depend on how deeply the drug suppressed the HPG axis. Short courses of oral contraceptives (under six months) allow FSH normalization within one to two cycles. Longer use may require three natural cycles before FSH reflects true ovarian reserve.

Testosterone is the slowest to clear from the gonadotropin perspective. Men who discontinue TRT after years of use may not recover baseline FSH for 3 to 12 months, and some experience permanent gonadotropin suppression depending on pre-existing testicular function. The Endocrine Society notes that "recovery of the HPG axis after prolonged exogenous testosterone is variable and may be incomplete" 2.

For patients unable to stop interfering medications (cancer patients on GnRH agonists, transplant patients on chronic glucocorticoids), document the drug exposure directly on the lab requisition. Interpreting FSH in these patients requires clinical context, not reference ranges. An FSH of 0.3 mIU/mL in a man on leuprolide is expected, not pathologic.